BM Sub-Journal: True body weight change, compliance and discontinuation of GLP-1 receptor agonists in T2DM patients

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a type 2 diabetes mellitus (T2DM) treatment with proven weight loss benefits in clinical trials

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a type 2 diabetes mellitus (T2DM) treatment with proven weight loss benefits in clinical trials

This study analysed the characteristics of weight change in UK GLP-1RA patients with T2DM and assessed adherence and drug discontinuation after 12 and 24 months of follow-up

This study investigated patients with T2DM from January 2009 to December 2017 and assessed 12- and 24-month weight change, adherence (proportion of days covered (PDC) ≥80%), and drug discontinuation (prescribing interval ≥ 90 days)

This study investigated patients with T2DM from January 2009 to December 2017 and assessed 12- and 24-month weight change, adherence (proportion of days covered (PDC) ≥80%), and drug discontinuation (prescribing interval ≥ 90 days)

RESULTS: Of the 589 patients who initiated GLP-1RA, 56.

Weight change at 12-month and 24-month follow-up in GLP-1RA-treated patients with type 2 diabetes

Weight change at 12-month and 24-month follow-up in GLP-1RA-treated patients with type 2 diabetes

Percentage of patients who persisted (n=530) and discontinued (n=589) GLP-1 RA treatment at 12 and 24 months

Percentage of patients who persisted (n=530) and discontinued (n=589) GLP-1 RA treatment at 12 and 24 months

Overall, one-third of patients lost clinically meaningful weight at 12 months

Overall, one-third of patients lost clinically meaningful weight at 12 months

Reference: Weiss T, Yang L, Carr RD, et al Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK BMJ Open Diabetes Research and Care 2022; 10:e002517.
doi: 10.
1136/bmjdrc-2021-002517 doi: 10.
1136/bmjdrc-2021-002517

Leave a message here